ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1471	National Cancer Institute	Html	en	Small Intestine Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of small intestine cancer.	illustrations 0.418999 duodenum. 0.42103 PDQ cancer information 0.903829 resectable leiomyosarcoma 0.536755 PDQ information 0.645092 Small intestine carcinomas 0.711426 multiple sites 0.521204 scientific images 0.511301 malignant lesions 0.542214 text 0.419438 cancer information summary 0.765692 National Institutes 0.515005 sentence 0.423056 breast cancer prevention 0.606867 author 0.434223 NCI’s PDQ 0.679179 PDQ Adult Treatment 0.75546 adenocarcinomas 0.421075 NCI PDQ cancer 0.783554 carcinoid tumors 0.53815 small intestine 0.82655 jejunum 0.420595 ileum 0.420633 relates 0.424246 resectable adenocarcinoma 0.544916	5-year survival rate 0.903147 common primary sarcoma 0.632045 content 0.419494 predominant modality 0.550555 literature 0.41999 overall 5-year survival 0.674093 National Cancer Institute 0.792644 trademark 0.418975 Editorial Board 0.520308 ability 0.4195 PDQ documents 0.647487 primary malignant tumors 0.647543 owner 0.419281 Visuals Online 0.515575 entirety 0.426542 Health 0.419895 cancer-related images 0.526463 permission 0.44717 NIH 0.422847 gastrointestinal malignancies 0.551608 resection 0.436749 duodenum 0.432045 policy statement 0.518223 independent review 0.515819	CLICK HERE
1485	National Cancer Institute	Html	en	Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of intraocular (eye) melanoma.	uveal melanoma 0.68476 Medium Tumor Trial 0.539127 charged-particle ebrt 0.585479 local tumor regrowth 0.547533 125I brachytherapy 0.543775 uveal melanomas 0.962507 Option Overview section 0.565872 local tumor recurrence. 0.544248 posterior uveal melanomas 0.679007 plaque radiation therapy 0.595583 tumor regression rates 0.537853 uveal tract melanomas 0.717461 late local radiation 0.532096 ocular melanoma 0.519667 histopathologically confirmed melanoma 0.546989 large choroidal tumors 0.551303 small melanomas 0.610711 brachytherapy 0.555626 all-cause mortality rates 0.515468 U.S. incidence rates 0.52364 local control rate 0.579941 melanoma metastasis-specific survival 0.54531 prominent tumor vascularity 0.525035 posterior melanomas 0.676788	large uveal melanomas 0.659428 patients 0.552792 visual acuity 0.646161 optic disc 0.638287 ciliary body 0.761795 small choroidal melanoma 0.601669 ciliary body melanoma 0.589002 medium-sized choroidal tumors 0.551291 relatively good outcomes 0.576295 tumors 0.574964 Treatment Option Overview 0.566892 tumor growth warrants 0.54471 posterior uveal tract 0.542964 tumor 0.654818 unequivocal tumor growth 0.619495 anterior ciliary body 0.517737 radiation therapy 0.658453 local tumor control 0.613746 ocular melanomas 0.634519 typical choroidal melanoma 0.592701 statistically significant differences 0.571591 small choroidal melanomas 0.778268 iris melanomas 0.919191	CLICK HERE
1512	National Cancer Institute	Html	en	Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of osteosarcoma/malignant fibrous histiocytoma of bone.	cancer treatment 0.407081 malignant tumor cells 0.349447 body 0.457542 type 0.332048 chemotherapy 0.334597 PDQ cancer information 0.39878 clinical trial search 0.334862 clinical trials 0.824706 Pediatric Treatment Editorial 0.299208 cancer information summary 0.360916 clinical trial 0.498576 kinase inhibitor therapy 0.337105 detailed pictures 0.314561 patients 0.324824 NCI PDQ cancer 0.313063 radiation therapy 0.384486 Treatment Editorial Board 0.303904 bone cancer 0.343085 treatment 0.712766 wide local excision 0.303347 magnetic resonance imaging 0.301911 new cancer treatments 0.298777 osteosarcoma cells 0.305575 NCI-supported cancer 0.30089	cancer cells 0.508672 standard treatment 0.304104 Cancer Information Service 0.301597 MFH 0.338322 specific cancer cells 0.314742 Recurrent osteosarcoma 0.349728 patient 0.335989 treatment clinical trials 0.338171 National Cancer Institute 0.390929 effects cancer treatment 0.325995 new treatment 0.35734 treatment clinical trial 0.302675 bone 0.549956 primary tumor 0.351503 nuclear magnetic resonance 0.304246 PDQ summary 0.321698 cancer clinical trials 0.368405 Combination chemotherapy 0.30296 tumor 0.52585 cancer information summaries 0.299038 comprehensive cancer information 0.299274 cancer 0.934486 osteosarcoma 0.560059 surgery 0.417923	CLICK HERE
1551	National Cancer Institute	Html	null	Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders.			CLICK HERE
1567	National Cancer Institute	Html	en	Metastatic Squamous Neck Cancer with Occult Primary Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of metastatic squamous neck cancer with occult primary.	cancer treatment 0.331255 neck muscles 0.258524 cancer spreads 0.287607 metastatic cancer 0.293108 malignant tumor cells 0.281382 body 0.321816 PDQ cancer information 0.347021 squamous cells 0.294186 clinical trial search 0.272504 external radiation treatment 0.262886 clinical trials 0.659393 cancer information summary 0.31748 clinical trial 0.463543 squamous cell cancer 0.363064 breast cancer prevention 0.264993 radical neck dissection 0.322726 patients 0.300058 earlier clinical trials 0.261657 treatment clinical trial 0.277097 PDQ Adult Treatment 0.268031 different types 0.294996 NCI PDQ cancer 0.286254 tests 0.272201 radiation therapy 0.490196 Treatment Editorial Board 0.283384	lung cancer cells 0.288937 currently used treatment 0.262475 metastatic squamous neck 0.988686 treatment 0.481959 Occult Primary Treatment 0.275159 new cancer treatments 0.27464 cancer cells 0.387801 Cancer Information Service 0.273937 PDQ Metastatic Squamous 0.312989 Hyperfractionated radiation therapy 0.272771 treatment clinical trials 0.300592 squamous neck cancer 0.954253 National Cancer Institute 0.34026 occult primary 0.527765 new treatment 0.321855 new treatments 0.258619 Cancer Care page 0.264657 primary tumor 0.396235 cancer research process 0.267043 cancer clinical trials 0.302055 treatment options 0.305059 cancer information summaries 0.272694 comprehensive cancer information 0.272807 occult primary tumor 0.271623	CLICK HERE
1656	National Cancer Institute	Html	null	Last Days of Life (PDQ®)–Health Professional Version	Expert-reviewed information summary about care during the last days to last hours of life, including common symptoms, ethical dilemmas that may arise, and the role of the oncologist in caring for patients and their families during this time.			CLICK HERE
2032	National Cancer Institute	Html	es	Exámenes de detección del cáncer de próstata (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar el cáncer de próstata.	or watchful waiting 0.527761 Prostate Cancer Group-4 0.536467 Koyama T 0.514342 estudio erspc 0.525762 Sin embargo 0.633101 Resnick MJ 0.514745 países cuáles factores 0.523397 detección versus 0.572904 Holmberg L 0.514356 ensayo plco 0.516954 Swedish Cancer Registry 0.524495 Ahmed HU 0.514521 jurisdicciones europeas colaboradoras 0.519184 Preventive Services Task 0.58607 Ovarian Cancer Screening 0.580102 consiguiente tratamiento 0.524752 Croswell JM 0.515275 estudio prostate testing 0.532458 Estados Unidos 0.630717 centro göteborg 0.570246 siguientes tasas 0.517703 Prostate Cancer Prevention 0.525333 PSA rutinarias 0.626469 FJ Jr 0.514192 evolución natural benigna 0.523168	centro sueco göteborg 0.523946 trascendencia clínica 0.542862 Lancet Oncol 0.516366 Eur Urol 0.51628 End Results 0.514418 Loeb S 0.514034 Scandinavian Prostate Cancer 0.583772 seguimiento diagnóstico 0.518794 Gen Intern Med 0.526679 lesiones prostáticas benignas 0.525347 radical prostatectomy 0.520653 Países Bajos 0.556513 Fan KH 0.51463 edad promedio 0.515679 Chou R 0.514768 PDQ Tratamiento 0.51809 European Randomized Study 0.573324 Intern Med 0.549412 Steineck G 0.514536 Services Task Force 0.584434 prostate cancer 0.738954 datos probatorios 0.915311 Prostate Intervention Versus 0.524636 Cancer Screening Trial 0.580497	CLICK HERE
2104	National Cancer Institute	Html	es	Prevención del cáncer de endometrio (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de endometrio y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	Surgical Adjuvant Breast 0.312551 Obstet Gynecol 0.324802 accessed july 0.303593 Iowa Women Health 0.308818 population-based case-control study 0.304331 available online 0.305054 Cancer Research Fund 0.306547 endometrial carcinoma 0.319197 Breast feeding practices 0.304731 American Cancer Society 0.323044 Prospective Investigation into 0.30657 Disease Control 0.304429 case-control study 0.307735 intentional weight loss 0.305807 risk factors 0.315161 colorectal cancer 0.312231 Cancer Causes Control 0.326606 Natl Cancer Inst 0.357685 Women's Health Study 0.306339 Women's Health Initiative 0.307967 PDQ Prevención 0.303492 Research On Cancer 0.312008 endometrial hyperplasia 0.31494 endometrial cancer 0.992212 Reproductive risk factors 0.308365	European Prospective Investigation 0.306481 investigation into cancer 0.322236 Women's Health 0.310973 endometrial cancer risk 0.612217 Cancer Facts 0.307157 Bowel Project 0.305155 Health Study 0.307565 Nutr Cancer 0.307216 dose-response meta-analysis 0.303563 Cancer Research 0.309943 National Cancer Institute 0.30655 epidemiological studies 0.307756 replacement therapy 0.303602 Breast Cancer Prevention 0.308767 endometrial carcinoma among 0.306561 Clin Oncol 0.303952 breast cancer 0.379165 systematic review 0.305375 PDQ Genetics 0.303535 physical activity 0.307794 Gynecol Cancer 0.308219 Breast Cancer Study 0.308595 National Surgical Adjuvant 0.309763 Women’s Health 0.303756	CLICK HERE
3566	National Cancer Institute	Html	en	Training	NCI offers training at laboratories and clinics in Maryland and at universities and institutions nationwide. These cancer training and career development opportunities cover a broad spectrum of disciplines for individuals at career stages ranging from high school and graduate students to scientists, clinicians, and health care professionals.	National Cancer Institute 0.966549		CLICK HERE
16648	National Cancer Institute	Html	en	Track 3: Oncology Product Research and Review for Postdoctoral Research Fellows	NCI and FDA collaborate to train physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety. Learn more about this cancer training program.	FDA medical product 0.724157 pharmacology/toxicology branch 0.567867 regulatory research 0.567201 manufacturing processes 0.657075 reviewer training 0.533228 FDA scientific review 0.647979 regulatory requirements 0.555708 regulatory meetings 0.534128 Medical Center Dr 0.604857 fellows 0.948854 product-related research 0.563223 molecular targeted therapy 0.645977 translational research 0.550405 manufacturing control 0.548537 research goals 0.538726 post-marketing surveillance 0.528754 quality control 0.651731 Regulatory Review Fellowships 0.633391 branch chief 0.620999 research activities 0.549015 pharmacology/toxicology reviews 0.559001 particular product division 0.677124 FDA Centers 0.6466 product standards 0.562937 quality assurance 0.652186	Review list 0.528745 training program 0.540221 various training activities 0.644892 relevant federal statutes 0.651561 formal training 0.557556 earliest start date 0.598748 critical ethical issues 0.628449 medical product development 0.721681 product research 0.592749 clinical trial design 0.65091 postdoctoral training 0.552346 product development 0.822368 regulatory presentations 0.533763 human research subjects 0.664846 guidance document development 0.635078 regulatory files 0.555901 principal investigators 0.629995 approval process 0.53653 NCI-FDA Research 0.537698 program time frame 0.62474 division director 0.626349 supplemental training 0.540819 regulatory experience 0.537743 cancer biology 0.538989	CLICK HERE